Lana McClements

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4746681/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia. Frontiers in Immunology, 2020, 11, 1864.	2.2	102
2	Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives. Cells, 2020, 9, 1503.	1.8	92
3	3D Bioprinted cancer models: Revolutionizing personalized cancer therapy. Translational Oncology, 2021, 14, 101015.	1.7	90
4	Risk of preâ€eclampsia in women taking metformin: a systematic review and metaâ€analysis. Diabetic Medicine, 2018, 35, 160-172.	1.2	70
5	Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway. Clinical Cancer Research, 2013, 19, 3881-3893.	3.2	63
6	RALA-mediated delivery of FKBPL nucleic acid therapeutics. Nanomedicine, 2015, 10, 2989-3001.	1.7	57
7	Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections. Frontiers in Bioengineering and Biotechnology, 2020, 8, 554.	2.0	49
8	FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer, 2019, 19, 351.	1.1	45
9	Elucidating the Pathogenesis of Pre-eclampsia Using In Vitro Models of Spiral Uterine Artery Remodelling. Current Hypertension Reports, 2017, 19, 93.	1.5	44
10	FKBPL Is a Critical Antiangiogenic Regulator of Developmental and Pathological Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 845-854.	1.1	38
11	FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. British Journal of Cancer, 2020, 122, 361-371.	2.9	38
12	Hypercapnic acidosis induces mitochondrial dysfunction and impairs the ability of mesenchymal stem cells to promote distal lung epithelial repair. FASEB Journal, 2019, 33, 5585-5598.	0.2	34
13	Stem cell-based approaches in cardiac tissue engineering: controlling the microenvironment for autologous cells. Biomedicine and Pharmacotherapy, 2021, 138, 111425.	2.5	33
14	Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation. Chemico-Biological Interactions, 2022, 351, 109738.	1.7	33
15	Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen. Oncogene, 2014, 33, 3441-3450.	2.6	31
16	The Anti-Migratory Effects of FKBPL and Its Peptide Derivative, AD-01: Regulation of CD44 and the Cytoskeletal Pathway. PLoS ONE, 2013, 8, e55075.	1.1	30
17	Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia. Current Hypertension Reports, 2020, 22, 37.	1.5	28
18	Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 26-41.	1.8	28

LANA MCCLEMENTS

#	Article	IF	CITATIONS
19	Extracellular Vesicles from Mesenchymal Stromal Cells for the Treatment of Inflammation-Related Conditions. International Journal of Molecular Sciences, 2021, 22, 3023.	1.8	27
20	Association of Nrf2, SOD2 and GPX1 Polymorphisms with Biomarkers of Oxidative Distress and Survival in End-Stage Renal Disease Patients. Toxins, 2019, 11, 431.	1.5	24
21	Plasma Amino Acids Metabolomics' Important in Glucose Management in Type 2 Diabetes. Frontiers in Pharmacology, 2021, 12, 695418.	1.6	24
22	FKBPL and SIRT-1 Are Downregulated by Diabetes in Pregnancy Impacting on Angiogenesis and Endothelial Function. Frontiers in Endocrinology, 2021, 12, 650328.	1.5	20
23	Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival. American Journal of Nephrology, 2019, 50, 115-125.	1.4	19
24	Overlapping pathogenic signalling pathways and biomarkers in preeclampsia and cardiovascular disease. Pregnancy Hypertension, 2020, 20, 131-136.	0.6	19
25	Service evaluation of diabetes management during pregnancy in a regional maternity hospital: potential scope for increased self-management and remote patient monitoring through mHealth solutions. BMC Health Services Research, 2019, 19, 662.	0.9	18
26	FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. Scientific Reports, 2020, 10, 21655.	1.6	17
27	Simple-to-Operate Approach for Single Cell Analysis Using a Hydrophobic Surface and Nanosized Droplets. Analytical Chemistry, 2021, 93, 4584-4592.	3.2	16
28	The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases. Current Molecular Pharmacology, 2015, 9, 165-179.	0.7	16
29	FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.	0.8	13
30	Characterisation of cardiac health in the reduced uterine perfusion pressure model and a 3D cardiac spheroid model, of preeclampsia. Biology of Sex Differences, 2021, 12, 31.	1.8	12
31	Evaluation of the diagnostic accuracy of current biomarkers in heart failure with preserved ejection fraction: A systematic review and meta-analysis. Archives of Cardiovascular Diseases, 2021, 114, 793-804.	0.7	10
32	Association between Galectin-3 levels within central and peripheral venous blood, and adverse left ventricular remodelling after first acute myocardial infarction. Scientific Reports, 2019, 9, 13145.	1.6	9
33	Impact of reduced uterine perfusion pressure model of preeclampsia on metabolism of placenta, maternal and fetal hearts. Scientific Reports, 2022, 12, 1111.	1.6	9
34	The diagnostic potential of oxidative stress biomarkers for preeclampsia: systematic review and meta-analysis. Biology of Sex Differences, 2022, 13, .	1.8	9
35	Considerations to Model Heart Disease in Women with Preeclampsia and Cardiovascular Disease. Cells, 2021, 10, 899.	1.8	7
36	GSTM1 Modulates Expression of Endothelial Adhesion Molecules in Uremic Milieu. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-12.	1.9	5

LANA MCCLEMENTS

#	Article	IF	CITATIONS
37	Mechanisms of heart failure with preserved ejection fraction in the presence of diabetes mellitus. Translational Metabolic Syndrome Research, 2020, 3, 1-5.	0.2	4
38	An Integrative Biomedical Informatics Approach to Elucidate the Similarities Between Pre-Eclampsia and Hypertension. Studies in Health Technology and Informatics, 2019, 264, 988-992.	0.2	3
39	FKBPL, a novel player in cardiac ischaemia and fibrosis. Journal of Molecular and Cellular Cardiology, 2020, 140, 5.	0.9	2
40	Non-viral gene delivery utilizing RALA modulates sFlt-1 secretion, important for preeclampsia. Nanomedicine, 2021, 16, 1999-2012.	1.7	2
41	MESENCHYMAL STEM CELLS INFLUENCE TROPHOBLAST AND ENDOTHELIAL CELL FUNCTIONALITY IMPORTANT FOR PREVENTION OF PRE-ECLAMPSIA VIA A NOVEL ANTI-ANGIOGENIC PROTEIN, FKBPL. Journal of Hypertension, 2018, 36, e154.	0.3	1
42	4â€The role of a novel anti-angiogenic protein, FKBPL, in angiogenesis associated with cardiac dysfunction. , 2018, , .		0
43	6â€The role of a novel angiogenesis related protein, FKBPL, in spiral uterine artery remodelling important for the pathogenesis of preeclampsia. , 2018, , .		0
44	Engaging hard-to-reach populations in research on health in pregnancy: the value of Boal's simultaneous dramaturgy. Arts and Health, 2020, 12, 71-79.	0.6	0
45	054 Potential New Treatment Based on FKBPL for Hypertension-Induced Cardiac Hypertrophy. Heart Lung and Circulation, 2020, 29, S62.	0.2	0
46	The importance of polymorphisms of regulatory and catalytic antioxidant proteins in chronic kidney disease. Medicinski Podmladak, 2021, 72, 25-33.	0.2	0
47	NOVEL MIRNAS AS TARGETS OF MESENCHYMAL STEM CELLS-BASED THERAPY FOR TREATMENT OF PREECLAMPSIA. Journal of Hypertension, 2021, 39, e26-e27.	0.3	0
48	Abstract LB-054: FKBPL as a novel therapeutic target and prognostic biomarker in high grade serous ovarian cancer. , 2018, , .		0
49	The influence of uremic serum and GSTM1 knockdown on redox homeostasis in HUVECs. Free Radical Biology and Medicine, 2021, 177, S82-S83.	1.3	0
50	Editorial: New Technologies for Women's Health. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	0